Topotecan

Learn and practice gentle yoga with indira ghosh, a native of kashmir, india, an experienced orthopedic nurse and 30 year veteran in yoga instruction and physical education.

Filter-binding method using Ah-probe hybridization to quantify top0 I-DNA complexes. Ten patients were tested. Topotecan produced marrow hypoplasia in the three patients shown in open symbols but not the other seven patients. Considering the small number of patients investigated and the different dose schedules used in this phase I study, there was no clear correlation between patient response to therapy and the magnitude of complex formation induced by Topotecan treatment in vitro. However, the interpatient variability in the production of Topotecan-stabilizedtop0 I-DNA complexes is noteworthy and suggests there may be differences in drug sensitivity of the cellular target in this small patient sample.
As in Table 2, Fig. 2 also depicts the selectivity to MMA, which decreased with increasing temperature from 260 up to 409 0C, and the selectivity to MA increases only slightly. Such a behavior implies a complex set of parallel and consecutive reactions, in which both reactant and products are consumed. The highest overall selectivity to. Multiple chemotherapy agents possess single-agent activity against SCLC, including cyclophosphamide, doxorubicin, vincristine, etoposide, nitrogen mustard, nitrosureas, and others.1 Recently, several new drugs with unique mechanisms of action also have proved active against SCLC. Among the more interesting new agents are paclitaxel Taxol; Bristol-Myers Squibb; Princeton, NJ ; and the camptothecin derivatives irinotecan Camptosar; Pharmacia and Upjohn; Bridgewater, NJ ; and topotecan Hycamtin; SmithKline Beecham; Pittsburgh, PA ; .3, 4 These new drugs are presently undergoing investigation in combination with other active agents. Although the role of the newer agents in the management of SCLC remains undefined, it is likely that some will become important components of standard chemotherapy regimens in the near future.5 Randomized trials have demonstrated the superiority of multiagent regimens over single-agent therapies in SCLC.6, 7 This includes single-agent oral etoposide in elderly or medically unfit patients.7, 8 Although multiple regimens yield approximately equivalent survival results, the combination of cisplatin and etoposide PE ; appears to have the best therapeutic index with fewer episodes of life-threatening toxicities. For example, Ihde and colleagues9 reported a 2% incidence of grade 3 or 4 myelosuppression with "standard"-dose PE. With such a low incidence of life-threatening myelosuppression, hematopoietic growth factors would rarely be necessary.10, 11 Except in rare circumstances, the addition of a third drug to this two-drug regimen has done little to improve overall efficacy. In general, two-drug regimens are associated with fewer severe toxicities and fewer septic deaths.1215 Also, PE is more easily administered with concurrent RT than other combination regimens, making it the preferred regimen for patients who are candidates for thoracic RT. For all the aforementioned reasons, PE is the initial chemotherapy choice for most SCLC patients, regardless of stage at presentation. Nevertheless, other combination regimens retain a role in selected circumstances. For example, where preexisting renal dysfunction or neuropathy exists or aggressive hydration is problematic, carboplatin can be substituted for cisplatin without apparent loss of therapeutic efficacy.16 19.
1 Randomised trial of single-agent carboplatin against threedrug combination of CAP cyclophosphamide, doxorubicin, and cisplatin ; in women with ovarian cancer. ICON Collaborators. International Collaborative Ovarian Neoplasm Study. Lancet 1998; 352: 1571-1576. McGuire WP, Hoskins WJ, Brady MF et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer [see comments]. N Engl J Med 1996; 334: 1-6. Stuart G, Bertelsen K, Mangioni C et al. Updated analysis shows a highly significant improved overall survival for cisplatin-paclitaxel as first line treatment of advanced ovarian cancer: mature results of the EORTC-GCCG, NO-COVA, NCIC CTG and Scottish Intergroup Trial. Proc Assoc Clin Oncol 1998; 17: 361a. Muggia FM, Braly PS, Brady MF et al. Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study. J Clin Oncol 2000; 18: 106-115. Piccart MJ, Green JA, Lacave AJ et al. Oxaliplatin or paclitaxel in patients with platinum-pretreated advanced ovarian cancer: a randomized phase II study of the European Organization for Research and Treatment of Cancer Gynecology Group. J Clin Oncol 2000; 18: 1193-1202. Rixe O, Ortuzar W, Alvarez M et al. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel. Biochem Pharmacol 1996; 52: 1855-1865. Fink D, Nebel S, Norris PS et al. Enrichment for DNA mismatch repair-deficient cells during treatment with cisplatin. Int J Cancer 1998; 77: 741-746. McGuire W, Rowinsky EK, Rosenshein NB et al. Taxol: a unique antineoplastic agent with significant activity in advanced ovarian epithelial neoplasms. Ann Int Med 1989; 111: 273-279. Swisher EM, Mutch DG, Rader JS et al. Topotecan in platinum- and paclitaxel-resistant ovarian cancer. Gynecol Oncol 1997; 66: 480-486. Rose PG, Blessing JA, Mayer AR et al. Prolonged oral etoposide as second-line therapy for platinum-resistant and platinum-sensitive ovarian carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 1998; 16: 405-410. Minasian L, Sarosy G, Dyer V et al. Phase II study of MGI114 in platinum resistant recurrent ovarian cancer. Proc Assoc Cancer Res 2000; 41: 861a. Statistical significance P 0.05 ; to the steady state value. Mean standard error. N : number of animals. CVR cerebral vascular resistance mm Hg ml 100 gm brain min ; . CBF cerebral blood flow ml 100 gm brain min ; . C.I. chemical index ml 100 gm brain min mm Hg and toradol. Topotecan Topotecan Hycamtin; GlaxoSmithKline, Philadelphia, PA ; is an active and well-established agent currently indicated [topotecan 1.5 mg m2 ; on days 1 through 5 of a 21-day cycle] for the treatment of relapsed metastatic ovarian cancer after failure of initial or subsequent chemotherapy. In several large phase II trials of patients with advanced ovarian cancer, tumor response rates ranged from 14% to 33% 15, 16, ; . In platinumsensitive patients, defined as those patients relapsing 6 months after completing platinum therapy, overall tumor response rates ranged from 19% to 33% 16, 18, ; . Additionally, topotecan is active in platinum-refractory patients, yielding tumor response rates of 14% to 18% 15, 16, ; . Stable disease was achieved in an additional 18% to 48% of patients receiving topotecan in these trials. In a trial conducted in platinumsensitive patients, median survival had not been reached at a follow-up of 21.5 months 18 ; . The main severe toxicity associated with topotecan is reversible, noncumulative neutropenia. Although the main toxicity is myelosuppression, the need for growth factor support, platelets, and red blood cell transfusions did not increase with the duration of topotecan treatment 9 ; . The nonhematologic toxicity profile of topotecan is generally favorable, with the topotecan dose level rarely limited because of nonhematologic toxicity. A recent analysis of clinical trial data for topotecan in the small-cell lung cancer setting found that elderly patients may be at higher risk for developing diarrhea during treatment.1 Fatigue, a common side effect of chemotherapy in patients with advanced cancer, may become severe during extended therapy. Alternative dosing and scheduling of topotecan are currently investigational and may provide additional treatment options in heavily pretreated patients 76 ; . Because the neutropenia observed with topotecan is noncumulative and the nonhematologic toxicity is rarely doselimiting, there has been interest in evaluating the potential of longer-term therapy 9 ; . McGuire et al. 18 ; first demonstrated the utility of prolonged topotecan in platinum-sensitive patients at relapse. In that study, a median of 6 cycles of topotecan was administered; consequently, a large proportion of patients continued on therapy beyond 6 cycles, with some receiving as many as 18 cycles. This finding, in part, is attributed to the high percentage of patients who achieved objective tumor response 33% ; or stable disease 48% ; as their best response. However, 9 of 15 patients who responded to topotecan elected to discontinue therapy before progression because of fatigue. In a second study of prolonged topotecan therapy, 33 patients with recurrent disease received a mean of 10 courses of therapy 9 ; . Of patients evaluable for response, 12 patients 1 patient with complete response and 11 patients with partial responses ; achieved an objective tumor response 38% ; , and 20 patients 63% ; had stable disease as a best response. Liposomal Doxorubicin Liposomal doxorubicin Doxil; Ortho Biotech, Bridgewater, NJ ; is an active agent indicated for the treatment of patients with disease that is refractory to both paclitaxel- and platinum.

505 b ; 2 ; and equivalent routes network of regional regulatory personnel to develop innovative registration strategies and accelerate time to market global hospital-focused sales and distribution platform strong relationships with generic oncology customers in uk, australia, italy, nordic, canada and established relationships in many other major global markets additional services such as compounding emerging, bringing mayne closer to end user of products management throughout organisation with proprietary pharmaceutical industry experience fy 2006 sales by category pro forma sales up by 1 6% 2006 products 82% compounding 5% contract manufacturing 13% emea 49% asia pac 24% n america 27% anti-cancer 47% anti-infective 10% biphosphonate 8% oncology other 6% pain management 3% non-oncology 26% fy 2006 sales by geographic region mayne’ s global presence – sales fy 2006 * 2006 pro forma sales revenue for the year ended 30 june 2006 americas 7m * emea 1m * asia pacific 4m * regional overview – emea * direct territories: belgium denmark finland france germany ireland italy netherlands norway portugal spain sweden uk 49% of revenue sales fy 2006 a1m + 19% ; key activities: direct sales in 13 countries; distributors in over 40 countries non-cytotoxic injectable manufacturing in wasserburg, germany aseptic compounding facilities in uk r& d and regulatory affairs * as at 30 june 2006 regional overview – asia pacific * direct territories: australia hong kong malaysia new zealand singapore 24% of revenue sales fy 2006 a4m + 22% ; key activities: direct sales in 5 countries; distributors in 3 countries cytotoxic and non-cytotoxic r& d and injectable manufacturing in mulgrave australia ; oral r& d manufacturing in salisbury australia ; cytotoxic api processing and injectable manufacturing jv in india under construction ; r& d and regulatory affairs * as at 30 june 2006 regional overview – americas * * as at 30 june 2006 direct territories: usa canada 27% of revenue sales fy 2006 a7m + 12% ; key activities: direct sales in usa and canada non-cytotoxic injectable manufacturing: aguadilla, puerto rico api processing: boulder, co, usa r& d and regulatory affairs global growth rate by therapeutic area 2005 % ; oncology continues to grow source: ims knowledge link; note that oncology refers to ims classes l1 and l 0 20 metabolic alimentary haematology cardio- vascular genito- urinary anti-infective oncology central nervous system respiratory growth drivers for oncology products cancer therapeutic class was fastest growing of top eight classes many business development opportunities for growth internal development to alliances and in-licensing to m& a ageing population results in increasing cancer incidence world health organisation who ; estimates a 50% increase in cancer cases from 10 million in 2000 to 15 million in 2020 lower levels of product obsolescence combination therapies widely used older “ proven” products are still widely used significant value of certain oncology products losing patent protection over the next 10 years 28% 1, 476 eloxatin® oxaliplatin ; selected injectable cytotoxic molecules: 10% 1, 000 zometa® zoledronic acid ; 1% 227 neupogen® g-csf ; selected injectable oncology related therapies: -3% 153 hycamtin® topotecan ; -3% 229 ellence® pharmorubicin® epirubicin ; 245% 376 alimta® pemetrexed ; 1% 732 10% gemzar® gemcitabine ; 12% 1, 408 taxotere® docetaxel ; growth rate vs 2004 global 2005 lmv * usd m ; * source: ims health, midas sales data, mat dec 2005 us, canada, uk, germany, france, italy, spain, australia and toremifene.
Antiretroviral therapy for HIV infection in adults and adolescents in resource-limited settings: towards universal access. Geneva, World Health Organization, 2006. Antiretroviral therapy for HIV infection in infants and children in resource-limited settings: towards universal access. Geneva, World Health Organization, 2006. WHO HIV prevention and treatment guidelines. Geneva, World Health Organization, 2006. Prequalification programme: access to HIV drugs and diagnostics of acceptable quality. Geneva, World Health Organization. Available at : mednet3.who.int prequal lists hiv suppliers Sources and prices of selected medicines and diagnostics for people living with HIV AIDS. Geneva, World Health Organization, 2005. WHO model formulary. Geneva, World Health Organization, 2004. Additional metabolic routes of topotecan include the glucuronidation of the hydrolyzed lactone moiety and n -demethylated topotecan and torsemide.

Aiken JW, Vane JR 1973 ; Intrarenal prostaglandin release attenuates the renal vasoconstrictor activity of angiotensin. J Pharmacol Exp Ther 184: 678-687 Assali NS, Holm LW, Seghal N 1962 ; Hemodynamic changes in fetal lamb in utero in response to asphyxia, hypoxia and hypercapnia. Circ Res 11: 423- 30 Campbell AGM, Dawes GS, Fishman AP, Hyroan Al 1967 ; Regional redistribution of blood flow in the mature fetal lamb. Circ Res 21: 229-235 ChalUs JRG, Dilley SR, Robinson JS, Thorbum GD 1976 ; Prostaglandins in the circulation of the fetal lamb. Prostaglandins 11: 1041-1049 and topotecan.
Amishima, M., Munakata, M., Nasuhara, Y., Sato, A., Takahashi, T., Homma, Y., Kawakami, Y., 1998: Expression of Epidermal Growth Factor and Epidermal Growth Factor Receptor Immunoreactivity in the Asthmatic Human Airway. Am. J. Respir. Critical Care Med. 157, 6, 1907-1912 and treprostinil.

Blockers in the treatment of coronary artery he recent withdrawal of rofecoxib disease. Predictably, many patients stopped Vioxx ; from the worldwide market their calcium blockers, resulting in a number has focused intense public scrutiny of acute coronary and cerebrovascular on drug safety. Although the US Food and events that would not otherwise have Drug Administration monitors drug safety occurred because of rises in previously well after product approval, some have raised controlled ; blood pressure. concerns about whether this system, which I all for drug safety, but I also for relies primarily upon voluntary reporting of patient safety. Media treatment of these adverse drug effects, is adequate to protect types of stories tends to glorify the the public from unsafe pharmaceuticals. whistleblower as a crusader for public safety, In his televised appearance before the and usually ignores the fine print of what is US Senate finance committee on 18 well known by professionals in the relevant November, Dr David Graham, associate field. Many members of the lay public director in the FDA's Office of Drug Safety, respond by acting impulsively--stopping claimed his own agency was "incapable of protecting [the public]" from other dangertheir drugs--rather than discussing their ous pharmaceuticals BMJ 2004; 329: 1253 ; . individual circumstances with their doctors He then listed five drugs that he considered to see whether the alleged risks outweigh potentially unsafe--the acne drug isotretinpotential benefits in their particular case. I no fan of the big drug companies oin Roaccutane ; , the weight loss drug sibuand have always opposed direct to consumer tramine sold as Reductil in Britain and advertising of prescription drugs and direct Meridia in the United States ; , the cycloto physician drug marketoxygenase-2 inhibitor valing. Both of these activities decoxib Bextra ; , the lipid are aimed at marketing, lowering drug rosuvastatin I all for drug rather than education. Crestor ; , and the asthma Overall the drug companies drug salmeterol Serevent ; . safety, but I spend more on marketing As a pulmonologist, I also for patient annually than they do on can only comment on the research and development, one drug on Dr Graham's safety list that I use frequently-- and that is outrageous in my salmeterol. I have kept abreast of the opinion. The 15% annual rate of increase in literature on this agent and aware of two drug costs including yearly price increases potential problems with it: the use of for well established prescription drugs, not salmeterol as opposed to a rapid onset just new "miracle" drugs ; , which makes bronchodilator such as salbutamol, or pharmaceuticals the single most profitable albuterol, as it is known in the United States ; sector in the US economy, is a major driver to treat acutely deteriorating asthma; and of higher health costs and higher health the increased death rate observed in the insurance premiums. This needs to be SMART salmeterol multi-center asthma changed if we are to bring health costs into a research trial ; and SNS salmeterol nationmore reasonable range. wide surveillance BMJ 1993; 306: 1034-7 But at the same time, we need to be caustudies, in which salmeterol was given for tious about taking at face value the maintenance without an accompanying statements made by Dr Graham and others inhaled steroid such as fluticasone--the who appear to be champions of the vulneraccompanying ingredient in Advair ; . In both able patient. In their efforts to promote of these instances, an excess of deaths has patient safety, they may sometimes be been reported, although the absolute causing more harm than good, and there increase in risk was rather small. Both of may be better ways to achieve the goals of these precautions are listed in a "black box" patient safety than making what I consider on the package insert and should be well irresponsible statements on nationally known to doctors using this drug. televised hearings. The total number of patients currently taking salmeterol worldwide is more than 24 million, and my own experience as well as that of my many colleagues who treat asthma has been overwhelmingly positive with this agent. Shortly after the news of Dr Graham's "list" was broadcast, I started receiving calls from asthmatic patients who stopped taking this drug in response to the television reports and, predictably, noted their asthmatic symptoms increasing. A similar phenomenon occurred about eight years ago when news reports highlighted risks associated with calcium channel. Lamellarin Figure 1 Structure of lamellarin derivatives Methodology: Structures and conformations of lamellarins were fully optimized at HF 3-21G level. Superimposition of lamellarins were performed by using Viewerpro. The 2.10 resolution X-ray crystal structure of human topoisomerase I 70 Kda ; in complex with the poison topotecan and covalent complex with a 22 base pair DNA duplex Protein Data Bank 1K4T ; was used as reference structure to model the lamellarins stabilization of topoisomerase I DNA complex. Then, hydrogen atoms and charges were added by Sybyl 7.0. The genetic algorithm implemented in the docking program Autodock 3.0 was used to explore lamellarins interaction modes with topoisomerase I-DNA complex. Results, Discussion and Conclusion: Superimposition of all lamellarin derivatives indicate different 3D structures among three groups. The structure of lamellarin in group 2 was divided into two planar portions, and the angle between them is about 9094o. On the other hand, a single bond between C8-C9 as in structure 1 was nonplanar structure. Superimposition in Figure 2 demonstrates, for example, the conformation of lamellarin K is different from the lamellarin D Figure 2a ; and M comformation as in Figure 2b. The root mean squares diviation of the redocking of topotecan was 1.15 and triac.
Read on to find out how some physicians answer some of their patients' commonly asked questions about BOTOX Cosmetic. Then talk to your own physician to decide if BOTOX Cosmetic is right for you and toradol. Agents such as camptothecin, cisplatin, or Adriamycin 24, 25 ; . When cells were treated with 10 M topotecan, about 70% of A549 CPT cells remained viable, whereas the viable cell number of parental A549 cells decreased to 20%. To examine whether A549 cells underwent apoptosis when the cells were treated with topotecan, cells were stained with propidium iodide, followed by examination of the appearance of the sub-G1 population using flow cytometry Fig. 1B ; . As shown in Fig. 1C ; , topotecan treatment increased the number of apoptotic sub-G1 fraction of A549 cells in a dose-dependent manner. Therefore, A549 cells underwent apoptosis after topotecan treatment. In contrast, A549 CPT cells exhibited resistance to topotecan-induced apoptosis because only 20% of A549 CPT cells underwent apoptosis after topotecan treatment for 48 h Fig. 1A, F ; . The number of sub-G1 fraction in A549 CPT cells was smaller than that in A549 cells Fig. 1C, f ; . We further examined the activity of DEVDases in the topotecantreated A549 and A549 CPT cells using fluorogenic-labeled tetrapeptides DEVD-AMC. Topotecan treatment activated the DEVDases in A549 cells in a dose-dependent manner Fig. 2A, ; . The activity in A549 CPT cells was hardly detectable Fig. 2A, f ; . The results also indicate that topotecan can stimulate A549 cells to undergo apoptosis. To clarify the activation of caspase-3 in A549 cells after topotecan treatment, we performed Western blot analysis using an antibody specifically recognizing the p85 cleaved fragment of PARP. PARP was a substrate of caspase-3 and was cleaved to produce the Mr 85, 000 cleaved fragment 28 ; . As shown in Fig. 2B, topotecan treatment increased the amount of p85 fragment in A549 cells but not in A549 CPT cells in a dose-dependent manner Fig. 2B ; . This result confirmed that topotecan treatment promoted caspase-3 activation in A549 cells and triazolam.
PAL ; , chalcone synthase CHS ; , flavanone 3-hydroxylase F3H ; , dihydroflavonol 4-reductase DFR ; , and anthocyanidin synthase ANS ; , ranged from 171 to 476 bp. The size of the fragment of glyceraldehyde-3-phosphate dehydrogenase GPD ; gene, used as control, was 333 bp AY123769 ; . For all fragments, similarity to the corresponding genes from other species was detected. In comparison with some related, previously reported sequences, each fragment exhibited 65% to 93% identity to the corresponding genes from other species in nucleotide sequences Table I ; . More than one different sequence was found from all the isolated cDNA fragments in sequencing analysis, but the ones showing highest homology with genes from other species were selected for the probes for the gene expression analysis.